Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Endostatin inhibits the pro-angiogenic action of basic fibroblast growth factor and vascular
endothelial growth factor in esophageal cancer.This study aims at assessing the efficacy and
safety of endostatin combined with concurrent chemoradiotherapy with Oxaliplatin in
esophageal cancer patients.